Previous 10 | Next 10 |
2024-03-04 09:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Enrollment continues in BEACON-IPF, a Phase 2b trial in patients with IPF SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasd...
2024-02-11 23:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-05 08:55:19 ET More on Pliant Therapeutics Pliant Therapeutics: Targeting Idiopathic Pulmonary Fibrosis Pliant Therapeutics GAAP EPS of -$0.70 beats by $0.08 Seeking Alpha’s Quant Rating on Pliant Therapeutics Historical earnings data for Plian...
Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320 mg reduced liver fibrosis markers ELF and PRO-C3 and showed improvements in h...
2024-01-03 12:41:31 ET Summary Today, we take a deeper look at Pliant Therapeutics, Inc., which has a promising lead asset and is targeting potentially lucrative indications in the treatment of fibrosis and related diseases. Analyst firms are optimistic about Pliant Therapeutics' ...
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9,...
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the presentation of preclinical...
Pliant Therapeutics Inc. (PLRX) is expected to report $-0.78 for Q3 2023
2023-11-09 17:33:44 ET More on Pliant Therapeutics Pliant Therapeutics' Multi-Pronged Fibrosis Play In Therapeutics Space, I Prefer Vicore Pharma Over Pliant Therapeutics Biggest stock movers today: Sirius XM, United Natural Foods, Immunovant and more Pliant ...
News, Short Squeeze, Breakout and More Instantly...
Pliant Therapeutics Inc. Company Name:
PLRX Stock Symbol:
NASDAQ Market:
On Tuesday, Pliant Therapeutics Inc (NASDAQ:PLRX) announced topline data from a Phase 2a PET Imaging trial of bexotegrast (PLN-74809) evaluatin...
12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an increase on placebo Improvement in FVC and reduction in cough severity reported in bexotegrast-treated patients at all timepoints compared ...
Pliant Therapeutics, Inc. (NASDAQ:PLRX) posted a loss for its first quarter on Monday. Pliant Therapeutics posted a quarterly loss of 78 cents per ...